Back to User profile » Dr Weide Zhong
Papers published by Dr Weide Zhong:
A Unique Approach: Biomimetic Graphdiyne-Based Nanoplatform to Treat Prostate Cancer by Combining Cuproptosis and Enhanced Chemodynamic Therapy
Xie W, Zhang Y, Xu Q, Zhong G, Lin J, He H, Du Q, Tan H, Chen M, Wu Z, Deng Y, Han Z, Lu J, Ye J, Zou F, Zhuo Y, Zhong W
International Journal of Nanomedicine 2024, 19:3957-3972
Published Date: 2 May 2024
The ALDOA Metabolism Pathway as a Potential Target for Regulation of Prostate Cancer Proliferation
Kuang Q, Liang Y, Zhuo Y, Cai Z, Jiang F, Xie J, Zheng Y, Zhong W
OncoTargets and Therapy 2021, 14:3353-3366
Published Date: 24 May 2021
Carbon Nanospheres Exert Antitumor Effects Associated with Downregulation of 4E-BP1 Expression on Prostate Cancer
Dong W, Luo Y, Zhang G, Zhang H, Liang Y, Zhuo Y, Liang Y, Zou F, Zhong W
International Journal of Nanomedicine 2020, 15:5545-5559
Published Date: 5 August 2020
Aberrant Expression of Citrate Synthase is Linked to Disease Progression and Clinical Outcome in Prostate Cancer
Cai Z, Deng Y, Ye J, Zhuo Y, Liu Z, Liang Y, Zhang H, Zhu X, Luo Y, Feng Y, Liu R, Chen G, Wu Y, Han Z, Liang Y, Jiang F, Zhong W
Cancer Management and Research 2020, 12:6149-6163
Published Date: 22 July 2020
Overexpression of BUB1B contributes to progression of prostate cancer and predicts poor outcome in patients with prostate cancer
Fu X, Chen G, Cai ZD, Wang C, Liu ZZ, Lin ZY, Wu YD, Liang YX, Han ZD, Liu JC, Zhong WD
OncoTargets and Therapy 2016, 9:2211-2220
Published Date: 15 April 2016
Combined overexpression of HIVEP3 and SOX9 predicts unfavorable biochemical recurrence- free survival in patients with prostate cancer
Qin GQ, He HC, Han ZD, Liang YX, Yang SB, Huang YQ, Zhou L, Fu H, Li JX, Jiang FN, Zhong WD
OncoTargets and Therapy 2014, 7:137-146
Published Date: 24 January 2014